



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

- 6 Bonelli MM, Mrak D, Perkmann T, Haslacher H, Aletaha D. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. *Ann Rheum Dis* 2021; published online May 6. <https://doi.org/10.1136/annrheumdis-2021-220408>.
- 7 Mrak D, Tobudic S, Koblischke M, et al. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. *Ann Rheum Dis* 2021; published online July 20. <https://doi.org/10.1136/annrheumdis-2021-220781>.
- 8 Predecki M, Clarke C, Edwards H, et al. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression. *Ann Rheum Dis* 2021; published online Aug 6. <https://doi.org/10.1136/annrheumdis-2021-220626>.
- 9 Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. *Ann Rheum Dis* 2021; published online June 14. <https://doi.org/10.1136/annrheumdis-2021-220647>.
- 10 Schulz E, Hodl I, Forstner P, et al. Association of naïve B cells with humoral response to SARS-CoV-2 vaccination. *medRxiv* 2021; published online Aug 31. <https://doi.org/10.1101/2021.08.11.21261898> (preprint).

Cutaneous vasculitis following COVID-19 vaccination



Published Online
September 30, 2021
[https://doi.org/10.1016/S2665-9913\(21\)00309-X](https://doi.org/10.1016/S2665-9913(21)00309-X)

Vaccines against SARS-CoV-2 represent a pivotal and effective countermeasure to contain the COVID-19 pandemic. Four vaccines are approved by the European Medicines Agency: two messenger RNA-based vaccines encoding the spike protein of SARS-CoV-2 (BNT162b2, Pfizer-BioNTech; mRNA-1273, Moderna) and two adenoviral vector-based vaccines encoding the spike protein (ChAdOx1 nCoV-19, AstraZeneca; Ad.26.COV2.S, Janssen).¹

As of Sept 23, 2021, more than 83 million vaccine doses were administered in Italy, with approximately a fifth of recipients receiving ChAdOx1 nCoV-19 vaccine.² Here, we report three cases of cutaneous vasculitis developing in previously healthy individuals shortly after vaccination with ChAdOx1 nCoV-19.

The clinical features of the patients are summarised in the appendix (p 1). Briefly, patient 1 was a 57-year-old man with a history of hypertension but no previous personal or family history of autoimmunity. Purpura developed 14 days following the first vaccine dose, initially affecting the lower limbs and rapidly spreading to the abdomen, torso, and head (figure). He received treatment with 1 mg/kg prednisone, which led to progressive resolution of skin lesions over 3 weeks. Patient 2 was a 58-year-old man, whose previous medical history was also unremarkable with no history of autoimmunity. Purpura developed 7 days following the second dose of vaccine, spreading from the lower limbs to the abdomen and trunk (appendix p 2). He received 0.5 mg/kg prednisone, to no clinical benefit, and then 1 mg/kg prednisone, with progressive resolution of skin lesions over 10 days. Patient 3 was a 53-year-old woman with no underlying health conditions or history of autoimmunity. Purpura developed 6 days following the first dose, affecting

the lower and upper limbs. She received treatment with 1 mg/kg prednisone, which led to a progressive resolution of skin lesions over 2 weeks.

All cases were investigated for laboratory abnormalities or organ involvements that are typically associated with small-vessel vasculitis. However, laboratory tests showed only non-specific increases in erythrocyte sedimentation rate and C-reactive protein (CRP); anti-neutrophil cytoplasmic antibodies, cytoplasmic anti-neutrophil cytoplasmic antibodies, perinuclear anti-neutrophil cytoplasmic antibodies, rheumatoid factor, cryoglobulins, antinuclear antibodies, anti-DNA, C3, C4, IgA, and serology for hepatitis B virus and hepatitis C virus were negative or normal. Chest imaging (ie, x-ray or CT), urinalysis, and a search for stool blood were also negative. A 5 mm skin punch biopsy was performed in patient 3, which showed only a mild lymphocytic perivascular infiltrate (appendix p 3). A histological diagnosis of leukocytoclastic vasculitis could not be formally confirmed in the absence of neutrophils, yet disruption of the vessel wall, or fibrinoid necrosis, the

See Online for appendix



Figure: Purpura in patient 1

clinical findings in these three patients were clearly indicative of this condition.

Although we cannot exclude the possibility that the onset of vasculitis following vaccination was coincidental, striking similarities between these three patients argue for pathogenic causality. Specifically, vasculitis developed in healthy individuals with no personal or family history of autoimmunity; clinical manifestations were similar and characterised by widespread cutaneous vasculitis with no visceral involvement; and there was a temporal association between vaccination and the development of clinical manifestations, with no other intercurrent inciting events. All patients underwent serologic testing for SARS-CoV-2 infection before vaccination and tested negative, indicating no previous primary infection: hence, vasculitis might have been triggered by maladaptive individual immune responses to a component of the vaccine.

The ChAdOx1 nCoV-19 vaccine contains recombinant adenoviral vectors encoding the spike protein of SARS-CoV-2, stabilisers, and immune adjuvants. It is possible that molecular mimicry might develop between the peptides that are expressed in the viral spike protein and in the host endothelial cells, particularly following non-specific adjuvant effects. Vasculitis can develop during COVID-19 because of direct endothelial damage,³⁻⁵ and coagulation disorders can develop following vaccination with ChAdOx1 nCoV-19 because of platelet-activating antibodies against platelet factor 4 (PF4).⁶ Thereby, we speculate that maladaptive immune activation induced by vaccination affects the endothelial layer or the coagulation cascade, ultimately inducing vasculitis in predisposed individuals.

SARS-CoV-2 infection has resulted in more than 4 million deaths worldwide, often due to excessive or aberrant host immune responses.⁷ The benefits of vaccination outweigh the risks,⁸ yet vaccination

of millions of individuals is unavoidably complicated by sparse immune-mediated adverse events, since proinflammatory stimulation can expose individual predisposition to the development of maladaptive immune responses.⁹⁻¹¹

GC led the study and wrote the report. GC, GDL, SC, RP, FC, and LD took clinical care of patients, obtained data, and contributed to drafting the manuscript. NR conducted histology evaluations. Written informed consent for publication was obtained from the patients. We declare no competing interests.

**Giulio Cavalli, Serena Colafrancesco, Giacomo De Luca, Nathalie Rizzo, Roberta Priori, Fabrizio Conti, Lorenzo Dagna cavalli.giulio@hsr.it*

Unit of Immunology, Rheumatology, Allergy and Rare Diseases (GC, GDL, LD) and Department of Pathology (NR), IRCCS San Raffaele Scientific Institute, Milan 20132, Italy; Vita-Salute San Raffaele University, Milan, Italy (GC, GDL, LD); Division of Rheumatology, Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University, Rome, Italy (SC, RP, FC); Saint Camillus International University of Health Science, UniCamillus, Rome, Italy (RP)

- Olliaro P, Torreale E, Vaillant M. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. *Lancet Microbe* 2021; **2**: e279–80.
- Presidenza del Consiglio dei Ministri. Report vaccini anti COVID-19. Sept 16, 2021. <https://www.governo.it/it/cscovid19/report-vaccini> (accessed Sept 23, 2021).
- McGonagle D, Bridgwood C, Ramanan AV, Meaney JFM, Watad A. COVID-19 vasculitis and novel vasculitis mimics. *Lancet Rheumatol* 2021; **3**: e224–33.
- Mehta P, Haskard DO, Laffan MA, Chambers RC, Hunt BJ. Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis. *Lancet Rheumatol* 2021; **3**: e171–72.
- Cavalli G, Colafrancesco S, Emmi G, et al. Interleukin 1alpha: a comprehensive review on the role of IL-1alpha in the pathogenesis and treatment of autoimmune and inflammatory diseases. *Autoimmun Rev* 2021; **20**: 102763.
- Eichinger S, Warkentin TE, Greinacher A. Thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination. Reply. *N Engl J Med* 2021; **385**: e11.
- Cavalli G, Larcher A, Tomelleri A, et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. *Lancet Rheumatol* 2021; **3**: e253–61.
- Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Haller C, von Kempis J. Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. *Lancet Rheumatol* 2021; **3**: e470–72.
- Boekel L, Hooijberg F, van Kempen ZLE, et al. Perspective of patients with autoimmune diseases on COVID-19 vaccination. *Lancet Rheumatol* 2021; **3**: e241–43.
- Boekel L, Kummer LY, van Dam KPJ, et al. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. *Lancet Rheumatol* 2021; **3**: e542–45.
- Hsu TY, D'Silva KM, Patel NJ, Fu X, Wallace ZS, Sparks JA. Incident systemic rheumatic disease following COVID-19. *Lancet Rheumatol* 2021; **3**: e402–04.



Haemophagocytic lymphohistiocytosis secondary to COVID-19: a case series

Published Online
August 16, 2021
[https://doi.org/10.1016/S2665-9913\(21\)00248-4](https://doi.org/10.1016/S2665-9913(21)00248-4)

A pathological, dysregulated immune response (ie, hyperinflammation) is a recognised complication of COVID-19.¹ The prototypical hyperinflammatory

syndrome secondary to infection is secondary haemophagocytic lymphohistiocytosis (sHLH), but the dominant hyperinflammatory phenotype in people